Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation Joanna C. ThornJoanna CoastDyfrig Hughes Current Opinion 26 March 2013 Pages: 155 - 161
Patient Preferences Versus Physicians’ Judgement: Does it Make a Difference in Healthcare Decision Making? Axel C. MühlbacherChristin Juhnke Review Article 26 March 2013 Pages: 163 - 180
Cost Effectiveness of Fecal DNA Screening for Colorectal Cancer: A Systematic Review and Quality Appraisal of the Literature Mairead SkallyPaul HanlyLinda Sharp Systematic Review 03 April 2013 Pages: 181 - 192
Time Costs Associated with Informal Care for Colorectal Cancer: An Investigation of the Impact of Alternative Valuation Methods Paul HanlyAlan Ó. CéilleachairLinda Sharp Original Research Article 03 April 2013 Pages: 193 - 203
Multilevel Analysis of the Influence of Patients’ and General Practitioners’ Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France Sylvain PichettiCatherine SermetLars L. Gustafsson Original Research Article 23 April 2013 Pages: 205 - 218
Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective Ronald C. WielageMegha BansalMichael Happich Original Research Article 25 April 2013 Pages: 219 - 236
Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome Stefan KaspersMichael B. RankeJoris Kleintjens Original Research Article Open access 07 May 2013 Pages: 237 - 249
Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years Reiko SatoGabriel Gomez ReyBrett Pinsky Original Research Article Open access 20 April 2013 Pages: 251 - 258
A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use David PriceYumi AsukaiIan Keyzor Original Research Article Open access 26 March 2013 Pages: 259 - 274
Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs Juliana MeyersYanni YuKeith L. Davis Original Research Article 16 May 2013 Pages: 275 - 286
A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States Richard NormanPaula CroninRosalie Viney Original Research Article 07 May 2013 Pages: 287 - 298
Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective Vijay N. JoishMonica Spilsbury-CantalupoSusan Boklage Original Research Article 12 April 2013 Pages: 299 - 304
Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison Carlos I. AlatorreVirginia HaynesDouglas Kelsey Correspondence 29 March 2013 Pages: 305 - 305
Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison” M. Haim ErderJipan XieVanja Sikirica Correspondence Open access 17 April 2013 Pages: 307 - 307
Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder M. Haim ErderJipan XieVanja Sikirica Erratum 21 March 2013 Pages: 309 - 309
